Recurrence detection in patients with triple-negative breast cancer following the current standard of care: a microsimulation model.

Sumeyye Samur¹, Oya Hoban², Ning Yan Gu³, Gebra Cuyun Carter³, Melanie Palomares³, Brad Arrick³, Emir Gursel², Yasin Yildiz², Turgay Ayer⁴, Jagpreet Chhatwal⁵, Heather A Parsons^6,7

¹Value Analytics Labs, Boston, Massachusetts, USA ssamur@valueanalyticslabs.com.

²Value Analytics Labs, Boston, Massachusetts, USA.

³Exact Sciences Corporation, Madison, Wisconsin, USA.

⁴H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology College of Engineering, Atlanta, Georgia, USA.

⁵Institute for Technology Assesment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

⁶Clinical Research Division, Fred Hutch Cancer Center; and Hematology & Oncology, University of Washington, Seattle, Washington, USA.

⁷Harvard Medical School, Boston, Massachusetts, USA.

PubMed DOI

Abstract

OBJECTIVES: Breast cancer is the most common cancer among women in the USA, accounting for approximately 31% of new cases and 15% of cancer-related deaths in females. Triple-negative breast cancer (TNBC) is the most lethal subtype with 29 months median overall survival. Despite curative-intent surgery and systemic adjuvant therapy, many patients remain at risk for recurrence. We developed a compre…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.